NextCure Announces Three New Members of its Scientific Advisory Board

NEXT STORY
USA Equities Corp. Launches Q-Scale Product to Meet Growing Mental Health End Market Demand
PREV STORY
Candel Therapeutics Appoints Mace L. Rothenberg, MD, as Senior Advisor to the Chief Executive Officer
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

VBL Therapeutics Announces New IND for an Investigator-Sponsored Phase 2 Trial of VB-111 in Recurrent Glioblastoma

author_avatar
NASDAQ Market News

FDA Grants Orphan Drug Designation (ODD) for Xeris Pharmaceuticals’ Ready-to-Use Glucagon for the Treatment of Hyperinsulinemic Hypoglycemia (HH). Results from Phase 2a Study in Post-Bariatric Hypoglycemia, Associated with HH, Published.

Chicago, IL, Feb. 08, 2018 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (“Xeris”), a specialty ...

author_avatar
NASDAQ Market News

Protalix BioTherapeutics Announces Positive Results from Phase II Clinical Trial of OPRX-106 for the Treatment of Ulcerative Colitis

Clinical Responses Observed in 67% of Patients and Clinical Remission Observed in 28% of ...

author_avatar
NASDAQ Market News